{"brief_title": "A Study to Compare the Effectiveness of Two Anti-HIV Drug Combinations", "brief_summary": "The purpose of this study is to compare two different anti-HIV drug combinations, one that contains nelfinavir (NFV) and one that does not. The best dosing schedule for indinavir (IDV) also will be studied.", "detailed_description": "Patients are stratified by screening plasma viral RNA results (50,000 copies/ml or below vs above 50,000 copies/ml) and randomized to 1 of 2 treatment arms. Group 1 receives IDV 3 times daily plus d4T/3TC twice daily. Group 2 receives IDV/NFV/d4T/3TC twice daily. Patients remain on study medications for 24 weeks and are seen at the clinic once every 4 weeks after entering the study. At each clinic visit, blood samples are taken to evaluate CD4 cell count and plasma HIV RNA levels.", "condition": "HIV Infections", "intervention_type": "Drug", "intervention_name": "Stavudine", "criteria": "Inclusion Criteria You may be eligible for this study if you: - Are HIV positive. - Have a viral load (level of HIV in your blood) of at least 10,000 copies/ml within 45 days of study entry. - Have a CD4 cell count of at least 100 cells/mm3 within 45 days of study entry. - Have a normal chest X-ray. - Have never taken protease inhibitors or 3TC. - Are 16 years of age or older. - Agree to practice sexual abstinence or use barrier methods of birth control (e.g., condoms). Exclusion Criteria You will not be eligible for this study if you: - Have an active opportunistic (AIDS-related) infection or cancer. - Have certain types of Kaposi's sarcoma. - Have hepatitis. - Have chronic diarrhea. - Have a history of certain medical conditions. - Are allergic to any of the study medications. - Are taking certain medications. - Are pregnant or breast-feeding.", "gender": "All", "minimum_age": "16 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00002430.xml"}